These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 18220734)

  • 21. Microbially synthesized modular virus-like particles and capsomeres displaying group A streptococcus hypervariable antigenic determinants.
    Chuan YP; Wibowo N; Connors NK; Wu Y; Hughes FK; Batzloff MR; Lua LH; Middelberg AP
    Biotechnol Bioeng; 2014 Jun; 111(6):1062-70. PubMed ID: 24338691
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A lipid core peptide construct containing a conserved region determinant of the group A streptococcal M protein elicits heterologous opsonic antibodies.
    Olive C; Batzloff MR; Horváth A; Wong A; Clair T; Yarwood P; Toth I; Good MF
    Infect Immun; 2002 May; 70(5):2734-8. PubMed ID: 11953422
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Group A streptococcal vaccine delivery by immunization with a self-adjuvanting M protein-based lipid core peptide construct.
    Olive C; Batzloff M; Horváth A; Clair T; Yarwood P; Toth I; Good MF
    Indian J Med Res; 2004 May; 119 Suppl():88-94. PubMed ID: 15232170
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Method for the synthesis of multi-epitopic Streptococcus pyogenes lipopeptide vaccines using native chemical ligation.
    Moyle PM; Olive C; Ho MF; Burgess M; Karpati L; Good MF; Toth I
    J Org Chem; 2006 Sep; 71(18):6846-50. PubMed ID: 16930036
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An efficient, chemically-defined semisynthetic lipid-adjuvanted nanoparticulate vaccine development system.
    Moyle PM; Hartas J; Henningham A; Batzloff MR; Good MF; Toth I
    Nanomedicine; 2013 Oct; 9(7):935-44. PubMed ID: 23428988
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Site-specific incorporation of three toll-like receptor 2 targeting adjuvants into semisynthetic, molecularly defined nanoparticles: application to group a streptococcal vaccines.
    Moyle PM; Dai W; Zhang Y; Batzloff MR; Good MF; Toth I
    Bioconjug Chem; 2014 May; 25(5):965-78. PubMed ID: 24712905
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lipid-core-peptide system for self-adjuvanting synthetic vaccine delivery.
    Skwarczynski M; Toth I
    Methods Mol Biol; 2011; 751():297-308. PubMed ID: 21674338
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Structure-activity relationship of a series of synthetic lipopeptide self-adjuvanting group a streptococcal vaccine candidates.
    Abdel-Aal AB; Batzloff MR; Fujita Y; Barozzi N; Faria A; Simerska P; Moyle PM; Good MF; Toth I
    J Med Chem; 2008 Jan; 51(1):167-72. PubMed ID: 18072728
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Protective and nonprotective epitopes from amino termini of M proteins from Australian aboriginal isolates and reference strains of group A streptococci.
    Brandt ER; Teh T; Relf WA; Hobb RI; Good MF
    Infect Immun; 2000 Dec; 68(12):6587-94. PubMed ID: 11083769
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Protection of mice from group A streptococcal infection by intranasal immunisation with a peptide vaccine that contains a conserved M protein B cell epitope and lacks a T cell autoepitope.
    Olive C; Clair T; Yarwood P; Good MF
    Vaccine; 2002 Jun; 20(21-22):2816-25. PubMed ID: 12034109
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synthesis, Characterization and Immunological Evaluation of Self-Adjuvanting Group A Streptococcal Vaccine Candidates Bearing Various Lipidic Adjuvanting Moieties.
    Fagan V; Hussein WM; Su M; Giddam AK; Batzloff MR; Good MF; Toth I; Simerska P
    Chembiochem; 2017 Mar; 18(6):545-553. PubMed ID: 28075053
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intranasal immunisation of mice with a streptococcal peptide-based vaccine.
    Relf W; Hayman W; Russell-Jones G; Good M
    Adv Exp Med Biol; 1997; 418():859-61. PubMed ID: 9331788
    [No Abstract]   [Full Text] [Related]  

  • 33. Synthesis of a Streptococcus pyogenes vaccine candidate based on the M protein PL1 epitope.
    Simerska P; Lu H; Toth I
    Bioorg Med Chem Lett; 2009 Feb; 19(3):821-4. PubMed ID: 19097790
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lipoamino acid-based adjuvant carrier system: enhanced immunogenicity of group a streptococcal peptide epitopes.
    Horvath A; Olive C; Wong A; Clair T; Yarwood P; Good M; Toth I
    J Med Chem; 2002 Mar; 45(6):1387-90. PubMed ID: 11882009
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Structure-activity relationship of lipid core peptide-based Group A Streptococcus vaccine candidates.
    Chan A; Hussein WM; Ghaffar KA; Marasini N; Mostafa A; Eskandari S; Batzloff MR; Good MF; Skwarczynski M; Toth I
    Bioorg Med Chem; 2016 Jul; 24(14):3095-101. PubMed ID: 27246859
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design of three-component vaccines against group A streptococcal infections: importance of spatial arrangement of vaccine components.
    Abdel-Aal AB; Zaman M; Fujita Y; Batzloff MR; Good MF; Toth I
    J Med Chem; 2010 Nov; 53(22):8041-6. PubMed ID: 21028828
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Group A streptococcal vaccines: facts versus fantasy.
    Steer AC; Batzloff MR; Mulholland K; Carapetis JR
    Curr Opin Infect Dis; 2009 Dec; 22(6):544-52. PubMed ID: 19797947
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A synthetic M protein peptide synergizes with a CXC chemokine protease to induce vaccine-mediated protection against virulent streptococcal pyoderma and bacteremia.
    Pandey M; Langshaw E; Hartas J; Lam A; Batzloff MR; Good MF
    J Immunol; 2015 Jun; 194(12):5915-25. PubMed ID: 25980008
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Parenteral and mucosal delivery of a novel multi-epitope M protein-based group A streptococcal vaccine construct: investigation of immunogenicity in mice.
    Dunn LA; McMillan DJ; Batzloff M; Zeng W; Jackson DC; Upcroft JA; Upcroft P; Olive C
    Vaccine; 2002 Jun; 20(21-22):2635-40. PubMed ID: 12034087
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mucosal vaccine made from live, recombinant Lactococcus lactis protects mice against pharyngeal infection with Streptococcus pyogenes.
    Mannam P; Jones KF; Geller BL
    Infect Immun; 2004 Jun; 72(6):3444-50. PubMed ID: 15155651
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.